VEGF and the quest for tumour angiogenesis factors
Abstract
The ability of tumours to induce new blood-vessel formation has been a major focus of cancer research over the past few decades, and vascular endothelial growth factor (VEGF) is now known to be central to this process. The quest for VEGF and other factors that promote tumour angiogenesis was initiated many decades ago, and a long and complicated path has led to the development of inhibitors of these molecules as anticancer agents. How did this field begin, and how have we arrived at our present understanding of the role of VEGF in tumour progression.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Necrosis promotes the expression of VEGFa, as dying tumor cells release signals that stimulate the growth of new blood vessels.
“Necrosis promotes the expression of VEGFa, as dying tumor cells release signals that stimulate the growth of new blood vessels33,53.”
From Self-supervised learning reveals clinically relevant histomorphological patterns for therapeutic strategies in colon cancer (2025) · cites this paper as [53]
Cites
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · see citing works
Self-citationTumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559 · see citing works
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653 · see citing works
Self-citationDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · see citing works
Self-citationThe Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144 · see citing works
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605 · see citing works
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589 · see citing works
The discovery of receptor tyrosine kinases: targets for cancer therapy
Gschwind, A., Fischer, O. M., & Ullrich, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1360 · Cited by 1,227 · see citing works
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056 · see citing works
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849 · see citing works
Self-citationTSC2 regulates VEGF through mTOR-dependent and -independent pathways
Brugarolas, J. B., Vazquez, F., Reddy, A., Sellers, W. R., & Kaelin, W. G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00187-9 · Cited by 528 · see citing works
Cao, R., Eriksson, A., Kubo, H., Alitalo, K., Cao, Y., & Thyberg, J. (2004) · Circulation Research · doi:10.1161/01.res.0000118600.91698.bb · Cited by 324 · see citing works
Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders
Qosa, H., Miller, D. S., Pasinelli, P., & Trotti, D. (2015) · Brain Research · doi:10.1016/j.brainres.2015.07.005 · Cited by 249 · see citing works
Hypoxia-regulated microRNAs in human cancer
Shen, G., Li, X., Jia, Y.-F., Piazza, G. A., & Xi, Y. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.195 · Cited by 164 · see citing works
Hypoxia signaling in cancer: Implications for therapeutic interventions
Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119 · see citing works
Id2 Mediates Tumor Initiation, Proliferation, and Angiogenesis in <i>Rb</i> Mutant Mice
Lasorella, A., Rothschild, G., Yokota, Y., Russell, R. G., & Iavarone, A. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.9.3563-3574.2005 · Cited by 111 · see citing works
Potentiation of Glucocorticoid Activity in Hypoxia through Induction of the Glucocorticoid Receptor
Leonard, M. O., Godson, C., Brady, H. R., & Taylor, C. T. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.4.2250 · Cited by 100 · see citing works
Han, J.-Y., Oh, S. H., Morgillo, F., Myers, J. N., Kim, E., Hong, W. K., & Lee, H.-Y. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji251 · Cited by 99 · see citing works
TOR kinase complexes and cell migration
Liu, L., & Parent, C. A. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201102090 · Cited by 87 · see citing works
Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update
Lin, F.-L., Wang, P.-Y., Chuang, Y.-F., Wang, J.-H., Wong, V. H. Y., Bui, B. V., & Liu, G.-S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.029 · Cited by 74 · see citing works
Liu, B., Polack, M., Coudray, N., Claudio Quiros, A., Sakellaropoulos, T., Le, H., Karimkhan, A., Crobach, A. S. L. P., van Krieken, J. H. J. M., Yuan, K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57541-y · Cited by 25 · see citing works
- Authors
- Ferrara, N.
- Affiliations
- Genentech (US)
- Corresponding author
- Ferrara, Napoleone
- ORCID
- Ferrara, Napoleone
- Venue
- Nature Reviews Cancer
- Published
- 2002-10
- Volume
- 2
- Issue
- 10
- Pages
- 795-803
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1982246723
- Cited by
- 1,536
- References
- 1
- Citations by year
- 2026: 45 · 2025: 42 · 2024: 42 · 2023: 46 · 2022: 46 · 2021: 49 · 2020: 67 · 2019: 55 · 2018: 52 · 2017: 61 · 2016: 77 · 2015: 69 · 2014: 79 · 2013: 103 · 2012: 74
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- vascular endothelial growth factor, tumor angiogenesis, angiogenesis inhibitors, anticancer agents, tumor progression, tumor vasculature
- MeSH terms
- Animals, Antibodies, Monoclonal, Eye, Humans, Lymphokines, Neoplasm Transplantation, Neoplasms, Neovascularization, Pathologic, Rabbits, Time Factors, Endothelial Growth Factors, DNA, Complementary, Intercellular Signaling Peptides and Proteins, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
